What is Claimed:

1. Use of a composition in the manufacture of a medicament for treating a disease or disorder related to allergy in a subject in need thereof, wherein the composition comprises a therapeutically effective amount of a bispecific binding protein against 2 different alarmins X and Y, wherein said bispecific binding protein consists of (a) an anti-alarmin X receptor IgG and (b) an anti-alarmin Y scFv and (c) a polypeptide linker, and wherein the composition is to be delivered to cells or tissues of the subject.
2. Use of a composition in the manufacture of a medicament for treating a disease or disorder related to allergy in a subject in need thereof, wherein the composition comprises a therapeutically effective amount of a bispecific binding protein against 2 different alarmins X and Y, wherein said bispecific binding protein consists of (a) an anti-alarmin X receptor IgG and (b) an alarmin Y receptor and (c) polypeptide linker, and wherein the composition is to be delivered to cells or tissues of the subject.
3. The use of claim 1 or 2, wherein the alarmin X receptor is IL-17RB.
4. The use of claim 1, wherein the alarmin Y is TSLP.
5. The use of claim 1, wherein the alarmin Y is IL-33.
6. The use of claim 2, wherein the alarmin Y receptor is ST2.
7. The use of claim 2, wherein the alarmin Y receptor is TSLPR.
8. The use of claim 1 or 2, wherein the anti-alarmin X receptor IgG is an antibody selected from the group consisting of an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, and an IgG4 antibody.
9. The use of claim 1 or 2, wherein the subject has clinical or pre-clinical asthma, atopic dermatitis, fibrotic disease, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, chronic obstructive pulmonary disease, chronic sinusitis, chronic rhinosinusitis with nasal polyps.
10. Use of a composition in the manufacture of a medicament for treating a disease or disorder related to allergy in a subject in need thereof, wherein the composition comprises a therapeutically effective amount of a bispecific binding protein that blocks (a) IL-25 and IL-33 signaling and/or (b) IL-25 and TSLP signaling, and wherein the composition is to be delivered to cells or tissues of the subjects.
11. The use of claim 10, wherein the subject has clinical or pre-clinical asthma, atopic dermatitis, fibrotic disease, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, chronic obstructive pulmonary disease, chronic sinusitis, chronic rhinosinusitis with nasal polyps.

12. The use of claim 10, wherein bispecific binding protein is an anti-IL-17RB/anti-human TSLP bispecific antibody.

13. The use of claim 10, wherein bispecific binding protein is an anti-IL-17RB/anti-human IL-33 bispecific antibody.

14. The use of claim 10, wherein bispecific binding protein is an anti-IL-17RB/human ST2 antibody-receptor fusion protein.

15. The use of claim 10, wherein bispecific binding protein is an anti-IL-17RB/human TSLPR antibody-receptor fusion protein.

16. The use of any one of claims 10 to 15, wherein the bispecific binding protein comprises a light chain variable region (VL) comprising a VL CDR1, VL CDR2, and VL CDR3 that have the amino acid sequences of SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5, respectively; and a heavy chain variable region (VH) comprising a VH CDR1, VH CDR2, and VH CDR3 that have the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, respectively.

17. The use of claim 16, wherein the VL and VH of the anti-IL-17RB antibody have the amino acid sequences of SEQ ID NO:33 and SEQ ID NO:32, respectively.

18. The use of claims 10 to 15, wherein the bispecific binding protein comprises a light chain sequence of SEQ ID NO: 33 and a heavy chain sequence selected from the group consisting of SEQ ID NOs: 60-75

19. The use of any of claims 1 to 17, wherein the bispecific binding protein is to be delivered to said cells or tissues intravenously, intramuscularly, subcutaneously, intracranially, intrathecally, intraventricularly, intraperitoneally, intranasally, parenterally, topically, or intradermally.

20. The use of any one of claims 1 to 19, wherein bispecific binding protein is to be delivered in combination with a second therapeutic agent.

21. The use of claim 20, wherein the second therapeutic agent is selected from the group consisting of a corticosteroid, a DNA methyltransferase (DNMT) inhibitor, an anti-IL17A antibody, an anti-IL12/IL23 antibody, an anti-IL23 antibody, an anti-IL17RA antibody, and a tyrosine kinase inhibitor.

22. The use of any one of claims 1 to 21, wherein the subject is a human subject and the cells or tissues of the subject are immune cells obtained and isolated from said subject.